Outcome of Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis and Refractory Hepatic Hydrothorax: A Systematic Review and Meta-analysis

Overview

Journal Indian J Radiol Imaging

Publisher Thieme

Specialty Radiology

Date 2024 Sep 25

PMID 39318562

Authors

Suprabhat Giri

Ranjan Kumar Patel

Taraprasad Tripathy

Mansi Chaudhary

Prajna Anirvan

Swati Chauhan

Mitali Madhumita Rath

Manas Kumar Panigrahi

Affiliations

Soon will be listed here.

Abstract

Around 5% of patients with cirrhosis of the liver develop hepatic hydrothorax (HH). For patients with refractory HH (RHH), transjugular intrahepatic portosystemic shunt (TIPS) has been investigated in small studies. Hence, the present meta-analysis aimed to summarize the current data on the outcome of TIPS in patients with RHH. From inception through June 2023, MEDLINE, Embase, and Scopus were searched for studies analyzing the outcome of TIPS in RHH. Clinical response, adverse events (AEs), mortality, and shunt dysfunction were the primary outcomes assessed. The event rates with their 95% confidence interval were calculated using a random-effects model. A total of 12 studies ( = 466) were included in the final analysis. The pooled complete and partial response rates were 47.2% (35.8-58.5%) and 25.5% (16.7-34.3%), respectively. The pooled incidences of serious AEs and post-TIPS liver failure after TIPS in RHH were 5.6% (2.1-9.0%) and 7.6% (3.1-12.1%), respectively. The pooled incidences of overall hepatic encephalopathy (HE) and severe HE nonresponsive to standard treatment after TIPS in RHH were 33.2% (20.0-46.4%) and 3.6% (0.4-6.8%), respectively. The pooled 1-month and 1-year mortality rates were 14.0% (8.3-19.6%) and 42.0% (33.5-50.4%), respectively. The pooled incidence of shunt dysfunction after TIPS in RHH was 24.2% (16.3-32.2%). RHH has a modest response to TIPS in patients with cirrhosis, with only half having a complete response. Further studies are required to ascertain whether early TIPS can improve the outcome of patients with cirrhosis and HH.

References

Krok K, Cardenas A . Hepatic hydrothorax. Semin Respir Crit Care Med. 2012; 33(1):3-10. DOI: 10.1055/s-0032-1301729. View

Rubinstein D, McInnes I, DUDLEY F . Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management. Gastroenterology. 1985; 88(1 Pt 1):188-91. DOI: 10.1016/s0016-5085(85)80154-2. View

Dariushnia S, Haskal Z, Midia M, Martin L, Walker T, Kalva S . Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol. 2015; 27(1):1-7. DOI: 10.1016/j.jvir.2015.09.018. View

Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum H, Rossle M . Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001; 13(5):529-34. DOI: 10.1097/00042737-200105000-00011. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Roussos A, Philippou N, Mantzaris G, Gourgouliannis K . Hepatic hydrothorax: pathophysiology diagnosis and management. J Gastroenterol Hepatol. 2007; 22(9):1388-93. DOI: 10.1111/j.1440-1746.2007.05069.x. View

Rajesh S, Philips C, Betgeri S, George T, Ahamed R, Mohanan M . Transjugular intrahepatic portosystemic shunt (TIPS) placement at index portal hypertensive decompensation (anticipant TIPS) in cirrhosis and the role of early intervention in variceal bleeding and ascites. Indian J Gastroenterol. 2021; 40(4):361-372. DOI: 10.1007/s12664-021-01179-3. View

Xiol X, Guardiola J . Hepatic hydrothorax. Curr Opin Pulm Med. 2000; 4(4):239-42. DOI: 10.1097/00063198-199807000-00011. View

Dhanasekaran R, West J, Gonzales P, Subramanian R, Parekh S, Spivey J . Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2009; 105(3):635-41. DOI: 10.1038/ajg.2009.634. View

10.

Gou X, Jia W, He C, Yuan X, Niu J, Xu J . Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients. Eur Radiol. 2022; 33(5):3407-3415. PMC: 10121519. DOI: 10.1007/s00330-022-09357-3. View

11.

Badillo R, Rockey D . Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014; 93(3):135-142. PMC: 4632908. DOI: 10.1097/MD.0000000000000025. View

12.

Johnston R, LOO R . HEPATIC HYDROTHORAX; STUDIES TO DETERMINE THE SOURCE OF THE FLUID AND REPORT OF THIRTEEN CASES. Ann Intern Med. 1964; 61:385-401. DOI: 10.7326/0003-4819-61-3-385. View

13.

Gordon F, Anastopoulos H, Crenshaw W, Gilchrist B, McEniff N, Falchuk K . The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997; 25(6):1366-9. DOI: 10.1002/hep.510250611. View

14.

Campos S, Gomes D, Sofia C . Transjugular intrahepatic portosystemic shunt in refractory hydrothorax - a contribution to an unexplored indication. Eur J Gastroenterol Hepatol. 2016; 28(6):661-6. DOI: 10.1097/MEG.0000000000000623. View

15.

Wilputte J, Goffette P, Zech F, Godoy-Gepert A, Geubel A . The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg. 2007; 70(1):6-10. View

16.

Jindal A, Mukund A, Kumar G, Sarin S . Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis. Liver Int. 2019; 39(11):2164-2173. DOI: 10.1111/liv.14200. View

17.

Jeffries M, Kazanjian S, Wilson M, Punch J, Fontana R . Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg. 1998; 4(5):416-23. DOI: 10.1002/lt.500040506. View

18.

Strauss R, Martin L, Kaufman S, Boyer T . Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol. 1994; 89(9):1520-2. View

19.

Giri S, Kale A, Shukla A . Efficacy and Safety of Transjugular Intrahepatic Portosystemic Shunt Creation for Budd-Chiari Syndrome: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2022; 33(11):1301-1312.e13. DOI: 10.1016/j.jvir.2022.07.022. View

20.

Lieberman F, HIDEMURA R, Peters R, Reynolds T . Pathogenesis and treatment of hydrothorax complicating cirrhosis with ascites. Ann Intern Med. 1966; 64(2):341-51. DOI: 10.7326/0003-4819-64-2-341. View